Adverse Event: Clinical Trials

2 trials for Adverse Event, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2

Follow Adverse Event: new trials by email Literature Review of Adverse Event trials Research Report on Adverse Event

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Acalabrutinib 2x100 MG Oral Capsule + alloSCT - Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease
Phase 2CompletedPolish Lymphoma Research Group292019-08-192025-01-16
LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy
Lifemel - Neutropenia, Adverse Event
Phase 2CompletedVitalMel392013-11-112020-09-24

Narrower conditions

Bronchiolitis Obliterans Syndrome (1)  ·  Leukemia, B-Cell (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Neoplasm, Residual (1)  ·  Neutropenia (1)

Broader conditions

Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Agranulocytosis (1)  ·  Bronchial Diseases (1)  ·  Bronchiolitis (1)  ·  Bronchiolitis Obliterans (1)  ·  Bronchitis (1)  ·  Chronic Disease (1)  ·  Cytopenia (1)  ·  Disease Attributes (1)  ·  Graft vs Host Disease (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Leukemia (1)  ·  Leukemia, Lymphoid (1)

Sponsors

Polish Lymphoma Research Group (1)  ·  VitalMel (1)

Countries

Poland (1)

Top investigators

Andrea Pietro Sponghini (1)  ·  Sebastian Giebel, Prof. (1)